Dr. Sam Sanderson is the Founder and President of Prommune, Inc. as well as Research Associate Professor in the Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center. He received his B.S degree in chemistry from the University of Utah, the M.S. degree in chemistry from Ohio State University, his Ph.D. in chemistry and biochemistry from Ohio State University, and did his postdoctoral training at the University of Arizona Department of Chemistry as a National Institutes of Health Research Fellow. He is the principal inventor of the EP67 platform technology, which is covered by 8 US patents, and has received over $2M in research funding from the National Institutes of Health. Dr. Sanderson is the author of 71 peer-reviewed publications and has had over 30 years of experience in research and development at the university and industrial levels. He established Prommune as a mechanism to translate the numerous research findings of the EP67 platform into commercially available therapeutic entities for invoking natural immune responses in the treatment of diseases in veterinary and human medicine applications and for generating vaccines.